Low-dose dopamine induces early recovery of recombinant interleukin-2--impaired renal function

Eur J Cancer. 1993;29A(8):1119-22. doi: 10.1016/s0959-8049(05)80300-4.

Abstract

Recombinant interleukin-2 (rIL-2) can produce impairment of renal function with hypotension, fluid retention, elevated blood urea nitrogen, oliguria and low fractional sodium excretion; these side-effects are a common cause of reduction or interruption of rIL-2 infusion. The aim of this study was to investigate the control and treatment of renal toxicity induced by rIL-2 therapy. Here we show that dopamine, at a low dose of 2 micrograms/kg/min, completely prevented renal toxicity induced by rIL-2. While continuing rIL-2 therapy, 24-h continuous infusion of low-dose dopamine produced a rapid normalisation of urine output and a significant decrease in serum creatinine levels and body weight (P < 0.01), with an early and complete recovery of the rIL-2--impaired renal function: mean recovery time of renal function in patients treated with dopamine was significantly lower (P < 0.05) than in nontreated patients (4.8 days vs. 10 days, respectively).

MeSH terms

  • Adult
  • Aged
  • Body Weight / drug effects
  • Creatinine / blood
  • Dopamine / administration & dosage
  • Dopamine / therapeutic use*
  • Female
  • Humans
  • Interleukin-2 / adverse effects*
  • Kidney Diseases / blood
  • Kidney Diseases / chemically induced*
  • Kidney Diseases / drug therapy
  • Kidney Neoplasms / blood
  • Kidney Neoplasms / therapy
  • Male
  • Melanoma / blood
  • Melanoma / therapy
  • Middle Aged
  • Oliguria / drug therapy
  • Recombinant Proteins / adverse effects

Substances

  • Interleukin-2
  • Recombinant Proteins
  • Creatinine
  • Dopamine